Clinical trials: asthma
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma
The purpose of this study is to evaluate the efficacy and safety of Flamboyant 200/12 association in adults with asthma.
- Trial name
- NCT04191447
- Testing
- Flamboyant 200/12, Budesonide / Formoterol 400/12
- Where
- Brazil
- Volunteers
- 134 people
- Sponsor
- EMS
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Asthma
Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma
The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects…
- Trial name
- NCT00064389
- Testing
- levalbuterol tartrate HFA MDI, racemic albuterol
- Where
- 96 sites in United States, Canada
- Volunteers
- 746 people
- Sponsor
- Sumitomo Pharma America, Inc.
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355
The purpose of this study if to investiagte the time course of PF-00258210 plasma concentration in the presence or absence of PF-00610335 administered via oral inhalation using dry powder inhalers
- Trial name
- NCT01043276
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Singapore
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma Control Level
Assessment of Asthma Control Level in Primary Care Setting in Malaysia
A prospective observational multi center study to assess the level of asthma control at Primary Care Setting; government health clinics (Klinik Kesihatan) in Malaysia.
- Trial name
- ASCOPE (NCT03804632)
- Where
- 10 sites in Malaysia
- Volunteers
- 1,011 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
- Trial name
- NCT03358147
- Testing
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg
- Where
- 232 sites in United States
- Volunteers
- 1,077 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)
This trial will compare the effectiveness of one dose of ciclesonide against one dose of budesonide in patients with asthma. The aim of the present trial is to compare the efficacy of ciclesonide versus budesonide on pulmonary…
- Trial name
- NCT00163384
- Testing
- Ciclesonide
- Where
- 19 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Healthy Volunteers, Asthma
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of single ascending doses of GSK3772847…
- Trial name
- NCT04366349
- Testing
- melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIB
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect additional preliminary clinical data related to the safety and clinical benefits of…
- Trial name
- NCT01923272
- Testing
- AlphaCore Device, AlphaCore
- Sponsor
- ElectroCore INC
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from peripheral blood after newly initiated montelukast therapy.
- Trial name
- NCT00398151
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 12 Weeks
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03226392
- Testing
- QAW039
- Where
- 142 sites in United States, Brazil and 16 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo.
- Trial name
- NCT05222529
- Testing
- Glycopyrronium bromide 25ug, Glycopyrronium bromide 12.5ug
- Where
- 23 sites in Bulgaria, Colombia and 6 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
Approximately 480 (120 per group) would need to complete the 6 weeks of treatments.
- Trial name
- NCT03834012
- Testing
- Beclomethasone 800 µg per day, Beclomethasone 400 µg per day, Beclomethasone 640 µg per day
- Sponsor
- Adamis Pharmaceuticals Corporation
Asthma
Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients
The primary objective of this trial is to investigate the safety and tolerability of BI 1060469 in healthy male and female subjects after oral administration of repeated rising doses of 3 mg, 10 mg, 25 mg, 75 mg, 150 mg and 250…
- Trial name
- NCT02126865
- Testing
- BI 1060469 Healthy, BI 1060469 asthmatics
- Where
- Germany
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma, Moderate Asthma
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.
- Trial name
- NCT02999711
- Testing
- REGN3500
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.